Pharmacokinetics of Amoxicillin/Clavulanic Acid Combination after Oral Administration of New Suspension Formulations in Human Volunteers Pharmacokinetics of coamoxiclave suspension
Iranian Journal of Pharmaceutical Sciences,
دوره 2 شماره 3 (2006),
1 تموز 2006
,
صفحه 129-136
https://doi.org/10.22037/ijps.v2.39636
چکیده
The pharmacokinetic properties of amoxicillin and clavulanic acid when used alone or in combination may be different and show interaction between these two agents that might decrease the absolute bioavailability of clavulanic acid. In an open, randomized, replicated Latin square under fasting condition, pharmacokinetics of new formulations of amoxicillin/clavulanic acid were compared with a reference formulation after single dose administration in 15 healthy male volunteers. Subjects were given equal molar doses of new suspension formulations of amoxicillin/clavulanic acid (312 mg/5 ml or 156 mg/5 ml) or Augmentin® (312 mg/5 ml) as the reference product. The wash-out period was one week between the administrations of these antibacterial agents. Blood samples were collected exactly before and after drug administration of each of the formulations at different time points up to 6 h. The concentrations of the antibiotics in plasma were measured by validated HPLC methods. Three formulations exhibited a similar mean C max of about 7.5±1.6 mg/l after Tmax of about 75±25 min. for amoxicillin and Cmax of about 2.5±0.6 mg/l after Tmax of about 61±15 min. for clavulanic acid. The AUC0-inf (total area under the curve) for amoxicillin was about 1278±172 g.min/ml and it was about 354±66 g.min/ml for clavulanic acid. There were no significant differences in pharmacokinetic parameters among these formulations. Pharmacokinetic parameters of amoxicillin and clavulanic acid found in this study were similar to previously
published data. The two generic formulations investigated in this study proved to be bioequivalent with brand-name Augmentin® with regard to the pharmacokinetic parameters Cmax, AUC0-t, AUC0-inf and Tmax. Moreover, the parametric confidence intervals (90%) for the ratio of the Cmax, Tmax, AUC0-t, and AUC0-Q values lie between 0.8-1.2 based on log transformed values. We may conclude that the two new formulations are bioequivalent with the reference suspension and could be considered equally effective in medicinal practice. Moreover, there were no interaction in pharmacokinetic parameters between amoxicillin and clavulanic acid. No serious adverse event was observed with the studied drugs.
- Amoxicillin
- Clavulanic acid
- Pharmacokinetics
- Suspension
ارجاع به مقاله
مراجع
[2] Neu HC, Wilson AP, Gruenberg RN. Amoxicillin/clavulanic acid: A review of its efficacy in over 38500 patients from 1979-1992. J Chemother 1993; 5: 67-93.
[3] Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15: 255-9.
[4] Barry AL, Pfaller MA, Fuchs PC, Pacher RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994; 38: 2419-25.
[5] Schaad UB, Casey PL, Copper DA, Ravenscroft AT. Pharmacokinetics of a syrup formulation of amoxicillin potassium clavulanat in children. J Antimicrob Chemother 1986; 17: 341-5.
[6] van Njekerk CH, van den Ende J, Hundt HKL, Louw EA. Pharmacokinetic study of a pediatric formulation of amoxicillin and clavulanic acid in children. Eur J Clin Pharmacol 1985; 29: 235-9.
[7] Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanate. Pediatr Infect Dis J 1996; 15: 949-54.
[8] White AR, Kaye C, Poupard JA, Pypstra R, Woodnutt J, Wynne B. Augmentine (amoxicillin /clavulanic) in the treatment of community acquired respiratory tract infection: A review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 (suppl 1):13-20.
[9] Navarro AS. New formulation of amoxicillin/clavulanic acid: A pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 2005; 44: 1097-115.
[10] Foulston M, Reading C. Assay of amoxicillin and clavulanic acid, the components of Augmentin, in biological fluids with HPLC. Antimicrob Agents Chemother 1982; 22: 753-62.
[11] FDA, center for drug evaluation and research (CDER), Guidance for Industry: Bioanalytical Method Validation May 2001.
[12] Code of federal regulation: Bioavailability and bioequivalence requirements. Vol. 21, part 320 (CFR 320). Washington DC, US Government Printing Office, 1998.
[13] FDA, center for drug evaluation and research (CDER), guidance for industry: Bioavailability and bioequivalence study for orally administrated drug products-general considerations. October 2000.
[14] Wardrop J, Ayres J W. Bioequivalence of a novel amoxicillin/clavulanate chewable tablet formulations. Res Commun Pharmacol Toxicol 1997; 2: 175-91.
[15] Schaad UB, Casey DL, Copper PA. Single dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients. Antimicrob Agents Chemother 1983; 23: 252-5.
[16] Molinaro M, Corona G, Fiorito V, Spreafico S, Bartolia N, Zoia C. Bioavailability of two different oral formulations of amoxicillin in healthy subjects. Arzneimittel Forschung 1997; 47:1406-10.
[17] Adam D, DeVisser I, Koeppe P. Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother 1982; 22: 353-7.
[18] Nelson JD, Kusmiesz H, Shelton S. Pharmacokinetics of potassium clavulante in combination with amoxicillin in pediatric patients. Antimicrob Agents Chemotherapy 1982; 21: 681-2.
- چکیده مشاهده شده: 98 بار
- IJPS_Volume 2_Issue 3_Pages 129-136 (English) دانلود شده: 31 بار